🇮🇳·12h agoIndustry
natco receives approval from central drug standard control organisation cdsco for semaglutide in india
Publisher
N
Natco Pharma
India
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Natco Pharma
- Region
- India
- Scope
- Industry
- Published
- July 29, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on natcopharma.co.in
Leave the platform to read the original full article on the publisher site.
Source: Natco Pharma
Scope: Industry
Related coverage
More related coverage
Chugai Pharmaceutical News/4h ago
令和8年熊本地震による被害への支援について
Chugai Pharmaceutical/4h ago
Support for Areas Affected by the 2026 Kumamoto Prefecture Earthquake
AbbVie News/5h ago
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie News/5h ago